ArticleScientific reports2025
Fractional order modeling of prostate cancer with pulsed treatment and the impact of effector cell killing and cell competition.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This manuscript illustrates a fractional-order mathematical model for prostate cancer (PC) growth under pulsed treatment, incorporating the effects of effector cell killing and competition between androgen-dependent (AD) and androgen-independent (AI) PC cells. We establish the existence and uniqueness of solutions using fixed-point theorems (Leray-Schauder and Banach) and investigate Ulam-Hyers stability to assess the model's solution stability under the fractional order. Numerical results are obtained via the fractional Euler method for simulation of the model at various fractional orders. Graphical results illustrate the model's dynamics, and the impact of key parameters, including the effector cell killing rate and inter-cell competition, is investigated. These findings provide insights into the complex interplay between treatment, immune response, and cancer cell dynamics, potentially informing therapeutic strategies for PC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.